HIV drug trogarzo gets a speed boost: new shorter injections tested

NCT ID NCT03913195

Completed Disease control Sponsor: TaiMed Biologics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether Trogarzo, an HIV medication, can be given as a quick 30-second injection into a vein or as a shot into a muscle, instead of the usual 15-minute infusion. Researchers enrolled 43 people, including some with HIV and some healthy volunteers, to check safety and drug levels. The goal is to make treatment more convenient for patients with multi-drug resistant HIV.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ibalizumab-uiyk (Trogarzo)
What this could lead to: If successful, this could make Trogarzo easier and faster to administer, potentially improving convenience for people living with HIV who need this treatment.
What could go wrong: This is a small, completed safety study (43 people) testing different ways to give a drug already approved for multi-drug resistant HIV. It does not test whether Trogarzo works better than current options, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV-1-INFECTION

Contacts and locations

Locations

Anthony Mills MD Inc.

Los Angeles, California, 90069, United States
Gary Richmond MD, PA

Fort Lauderdale, Florida, 33316, United States
North Texas Infectious Disease Consultants

Dallas, Texas, 75246, United States
Orlando Immunology Center

Orlando, Florida, 32803, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.